All In Biotech

Drug Trial Radar · NCT06176365

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

A Phase III, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of Survodutide Administered Subcutaneously Compared With Placebo in Patients With Obesity Disease in Japanese

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

274

Actual

Start

Jan 16, 2024

Primary completion

Dec 3, 2025

Study completion Dec 3, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 35 kg/m² or more and at least one health problem related to their weight, or * a BMI of 27 kg/m² or more and at least two health problems related to their weight. People who have either type 2 diabetes, high blood pressure, or increased blood lipids can take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.

Conditions

  • Obesity

Interventions

  • SurvodutideDrug

    once weekly subcutaneous injection

  • Placebo matching survodutideDrug

    once weekly subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight from baseline to Week 76Time frame: at baseline, at week 76
  2. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76Time frame: at baseline, at week 76

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Hosokawa Surgery Clinic

    Aichi, Nagoya, Japan

  • Nagoya City University Hospital

    Aichi, Nagoya, Japan

  • Chiba University Hospital

    Chiba, Chiba, Japan

  • Gifu University Hospital

    Gifu, Gifu, Japan

  • Jiyugaoka Yamada Clinic

    Hokkaido, Obihiro, Japan

  • Yamasaki Family Clinic

    Hyogo, Amagasaki, Japan

  • Kobe University Hospital

    Hyogo, Kobe, Japan

  • Motomachi Takatsuka Naika Clinic

    Kanagawa, Yokohama, Japan

  • Morinagaueno Clinic

    Kumamoto, Kumamoto, Japan

  • Yoshimura Clinic

    Kumamoto, Kumamoto, Japan

  • Medical Corporation KEISEIKAI Kajiyama Clinic

    Kyoto, Kyoto, Japan

  • Ijinkai Takeda General Hospital

    Kyoto, Kyoto, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Osaka, Japan

  • OCROM Clinic

    Osaka, Suita, Japan

  • Saino Clinic

    Saitama, Tokorozawa, Japan

  • Dojinkinenkai Meiwa Hospital

    Tokyo, Chiyoda-ku, Japan

  • Suidoubashi Medical Clinic

    Tokyo, Chiyoda-ku, Japan

  • Tokyo-Eki Center-building Clinic

    Tokyo, Chuo-ku, Japan

  • Tokyo Center Clinic

    Tokyo, Chuo-ku, Japan

  • Fukuwa Clinic

    Tokyo, Chuo-ku, Japan

  • Tokyo Asbo Clinic

    Tokyo, Chuo-ku, Japan

  • New Medical Research System Clinic

    Tokyo, Hachioji, Japan

  • Shimamura Kinen Hospital

    Tokyo, Nerima-ku, Japan

  • Clinical Research Hospital Tokyo

    Tokyo, Shinjuku-ku, Japan

  • HS Clinic

    Tokyo, Shinjuku-ku, Japan

  • ToCROM Clinic

    Tokyo, Shinjyuku-ku, Japan

  • Shinei Medical Healthcare Clinic

    Tokyo, Suginami-ku, Japan

  • Ikebukuro Metropolitan Clinic

    Tokyo, Toshima-ku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.